gHealth Research Director wins prize for new heart disease drug

  • EpiCor Therapeutics wins €20,000 prize

Dr Chris Watson from Queen’s University Belfast is a co-founder of EpiCor Therapeutics, an early-stage biotech start-up, that won University College Dublin’s (UCD) 2016 Start-Up of the Year Award, after being declared overall winner of the 2016 Venture Launch Accelerator Programme on 17 November 2016. EpiCor Therapeutics is developing new disease-modifying treatments that target the mechanisms underlying the development of heart failure. The initial focus of EpiCor Therapeutics is to re-purpose an existing drug, 5-azacytidine, for the treatment of a devastating heart disease called hypertrophic obstructive cardiomyopathy (HOCM). The most extreme form of the disease currently affects around 175,000 people, with associated annual healthcare costs of over $1 billion, in the US alone.

Caption: Pictured (l-r) are co-founders of EpiCor Therapeutics, an early-stage biotech start-up, Dr Chris Watson (QUB), Dr Nadia Glezeva (UCD) and Dr John Baugh (UCD).